An immunohistochemistry and histopathological study of ankaferd blood stopper in a rat model of cervical inflammation

OBJECTIVE: Ankaferd Blood Stopper (ABS) is a medicinal plant extract used topically as a hemostatic, anti-inflammatory, and anti-oxidant agent. Its cytoprotective effect mainly depends on its pleiotropic properties by modulating inflammatory mediators such as IL-1β, IL-6, and TNF-α. This study aims to test the possible therapeutic effect of ABS in the treatment of erosive and inflammatory conditions occurring in the uterine cervix.

METHODS: Twenty-four female Wistar Albino rats were used in the present study. Trichloracetic acid was applied intravaginally to establish an experimental rat model of cervicitis. The rats were randomly divided into three groups: group I (injury), group II (injury+isotoinc saline), and group III (injury+ABS). After 3 estrous cycles of ABS and isotonic saline treatment, the amount of inflammation, vascular congestion and erosion were evaluated in the cervical tissues by using a modified semi-quantitative scale of 0-3. Immunohistochemical staining with monoclonal antibodies against IL-1β was also performed.

RESULTS: Compared with group I and II, the ABS group showed the least inflammatory cell infiltration, vascular congestion and cervical erosion, compared with the ABS group prominent IL-1β staining observed in group I and group II.

CONCLUSION: Our data suggest that ABS is a highly effective alternative to induce normal cervical epithelium and can be used safely in the treatment of cervical inflammation with or without cervical erosion.

Medienart:

E-Artikel

Erscheinungsjahr:

2019

Erschienen:

2019

Enthalten in:

Zur Gesamtaufnahme - volume:65

Enthalten in:

Revista da Associacao Medica Brasileira (1992) - 65(2019), 2 vom: 14. Feb., Seite 183-190

Sprache:

Englisch

Beteiligte Personen:

Beyazit, Fatma [VerfasserIn]
Buyuk, Basak [VerfasserIn]

Links:

Volltext

Themen:

Ankaferd blood stopper
Interleukin-6
Journal Article
Plant Extracts
Tumor Necrosis Factor-alpha

Anmerkungen:

Date Completed 03.04.2019

Date Revised 03.04.2019

published: Print

Citation Status MEDLINE

doi:

10.1590/1806-9282.65.2.183

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM295152192